New hope for advanced cancers: JANX008 enters human testing
NCT ID NCT05783622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all standard treatments without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Laura and Isaac Perlmutter Cancer Center NYU Langone Health
New York, New York, 10016, United States
-
Ohio State University Hospital
Columbus, Ohio, 43210, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Christ Hospital Cancer Center
Cincinnati, Ohio, 45219, United States
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California San Diego Moores Cancer Center
San Diego, California, 92093, United States
-
University of California, Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30308, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?